$135.87+2.12% · 3M
Moving avg
1W+3.12%
1M+3.40%
3M+2.12%
6M-12.79%
YTD+11.74%
1Y+13.21%
3Y+70.16%
5Y+91.69%
52-week range
$108.4656% of range$157.29
Company health
Value2/6
Growth1/6
Profitability6/6
Health3/6
Dividend4/6
Bull vs bear
Strengths
- Analysts see 17% upside to a $159 target
- Analyst consensus is "Buy"
- Strong 29% net margin
- High return on equity (4216%)
Risks
No obvious red flags from the metrics.
Key statistics
Valuation
Market cap
$168.69B
Enterprise value
$175.09B
P/E ratio (TTM)
17.43x
P/S ratio (TTM)
5.40x
EV/EBITDA
12.49x
Per share & returns
EPS (TTM)
$7.42
Dividend yield
2.49%
Beta (1Y)
0.34
30-day change
+3.40%
Trading
Volume (24h)
5.50M
Previous close
$135.77
Shares outstanding
1.24B
About Gilead Sciences, Inc.
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
Symbol
GILD
Gilead Sciences, Inc. is a large-cap healthcare company in the Drug Manufacturers - General industry. Its shares are listed on NASDAQ (United States) and trade under the ticker GILD.
Frequently asked questions
What is Gilead Sciences, Inc.'s market cap?
Gilead Sciences, Inc. (GILD) has a market capitalization of $168.69B.
What is Gilead Sciences, Inc.'s P/E ratio?
Gilead Sciences, Inc. trades at a price-to-earnings (P/E) ratio of 17.43.
What exchange does GILD trade on?
GILD trades on NASDAQ.
Appears in
Compare & explore
Eli Lilly and CompanyLLY
$1,220.51+0.45%
$1.15T cap
Johnson & JohnsonJNJ
$260.86+0.41%
$628.65B cap
AbbVie Inc.ABBV
$248.66-0.57%
$439.33B cap
UnitedHealth Group IncorporatedUNH
$405.59+0.85%
$368.33B cap
Roche Holding AGSWX: ROP
CHF 365.50-0.92%
$357.92B cap
Merck & Co., Inc.MRK
$132.93+1.92%
$328.31B cap
Novartis AGSWX: NOVN
CHF 124.20-1.32%
$290.41B cap
AstraZeneca PLCLON: AZN
£117.02-1.20%
$244.93B cap